GENETIC EDITING OF TARGET GENES TO ENHANCE NATURAL KILLER CELL FUNCTION

Title:

GENETIC EDITING OF TARGET GENES TO ENHANCE NATURAL KILLER CELL FUNCTION

Document Type and Number:

WIPO Patent Application WO/2024/030970

Kind Code:

A3

Abstract:

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are genetically edited, for example, using Crispr/Cas, to modulate, reduce or otherwise eliminate expression of one or more endogenous genes. In several embodiments, the edited cells are engineered to express a chimeric antigen receptor targeting a tumor antigen, for example CD19, ligands of the NKG2D receptor, CD70, and/or BCMA, among others. In several embodiments, the editing enhances one or more aspects of the efficacy of the immune cells in cellular immunotherapy including cytotoxicity (e.g., ADCC) and/or persistence.

More Like This:

WO/2023/083298	ANTI-ICOSL ANTIBODY FUSION PROTEIN AND USE THEREOF
WO/2023/108936	NEUTRALIZING ANTIBODY CAPABLE OF BINDING TO SARS-COV-2 VIRUS AND USE THEREOF
WO/2016/028672	ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

Inventors:

TRAGER JAMES (US)
CHAN IVAN (US)
GUO CHAO (US)

Application Number:

PCT/US2023/071537

Publication Date:

April 11, 2024

Filing Date:

August 02, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

NKARTA INC (US)

International Classes:

C07K16/28; C07K14/705; C07K14/725; C12N5/078; C12N5/10; C12N15/90; A61K38/17; A61K38/20; C07K14/54; C07K14/715

Attorney, Agent or Firm:

LOZAN, Vladimir, S. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: CELL-LADEN BIOINK CIRCULATION-ASSISTED INKJET-BASED BIOPRINTING TO MITIGATE CELL SEDIMENTATION AND A...

Next Patent: RESTRICTED TARGET WAIT TIME INTERFERENCE DETECTION AND MANAGEMENT